Lifeline for cancer patients: drug continuation study offers hope

NCT ID NCT07172919

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study allows people with advanced solid tumors who have a specific KRAS gene mutation (G12C) to keep receiving the drug sotorasib (alone or with panitumumab) after their original clinical trial ends. The goal is to monitor safety and side effects for those who are still benefiting. About 14 adults who are already on this treatment in an Amgen-sponsored study can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Leon Berard

    RECRUITING

    Lyon, 69008, France

  • Evangelische Lungenklinik

    RECRUITING

    Berlin, 13125, Germany

  • Florida Cancer Specialists - Fort Myers

    RECRUITING

    Fort Myers, Florida, 33901, United States

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    RECRUITING

    Roma, 00168, Italy

  • Henry Dunant Hospital Center

    RECRUITING

    Athens, 11526, Greece

  • National Hospital Organization Hokkaido Cancer Center

    RECRUITING

    Sapporo, Hokkaido, 003-0804, Japan

  • Scientia Clinical Research Ltd

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 40705, Taiwan

  • Theagenion Cancer Hospital

    RECRUITING

    Thessaloniki, 54007, Greece

  • Universitaetsspital Basel

    RECRUITING

    Basel, 4031, Switzerland

  • University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.